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Abstract 
Capsules are a widely used oral dosage form due to their simplicity and ease of manufacture. They are 
equally popular for both pharmaceutical and nutraceutical products and since they do not need 
extensive formulation development; it is a dosage form of choice for new drugs undergoing animal or 
clinical trials. In addition to the standard hard-gelatin or cellulose-based vegetarian capsules, functional 
capsules such as those with built-in gastroresistance would be of great value. In this work, commonly 
used enteric polymers were investigated for the production of hard-capsules. The polymers used in this 
study included cellulose derivatives (HPMC AS-LF and HP-55) and acrylic/methacrylic acid derivatives 
(EUDRAGIT L100 and S100). A range of concentrations of polymers and plasticisers were tested to 
optimise the formulation for the production of capsule shells with desirable physicochemical and 
gastroresistance characteristics. Drug release from optimised capsules produced from HPMC AS-LF, 
HP-55, EUDRAGIT L100 and S100 was shown to be comparable to drug release from corresponding 
polymer-coated tablets in both compendial and physiological bicarbonate buffer. In summary, herein 
we report a simple method for producing enteric capsule shells which do not need an additional coating 
step which, if validated at large scale, can significantly reduce the cost of manufacturing of conventional 
enteric coated dosage forms and are also likely to improve the inter-tablet variability in post-gastric drug 
release inherent in coating variability in conventional coated dosage forms. 
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1. Introduction 
Capsules are one of the most common solid dosage forms employed for oral administration of active 
ingredients. With a global market valued at US$1.4bn in 2016 and an expected annual growth rate of 
7.3%, the empty capsule market is predicted to be worth roughly US$2.9bn in 2026 
(FutureMarketInsights, 2016). Capsules are relatively simple to use compared with tablets which need 
more formulation development, take longer to produce and quality control. Capsules also present a 
more convenient delivery system for nutraceuticals (often powders) without the need to develop a 
complex formulation. Also, for drugs undergoing animal or clinical trials, capsules are often employed 
their simplicity and quick formulation turnaround for early stages of drug development.  
Capsules can be manufactured in different sizes and materials, depending on their main purpose and 
content. Even though other materials are used, the large majority of capsules are still produced using 
gelatin (type A, type B and from fish bones) (Murachanian, 2010). Other materials were developed to 
meet the demand for non-animal based capsules which would address a growing need for halal and 
vegetarian/vegan markets (FutureMarketInsights, 2016). The most common alternatives are HPMC, 
pullulan and starch based capsules (Capsugel®, 2019c; Qualicaps®, 2019; Roxlor, 2019) which, 
although being a good substitute for gelatin, have limitations particularly when intended for enteric 
formulations as none of these materials have pH-dependant solubility. 
Nevertheless, when a gastroresistant formulation is required, the most conventional and common 
practice is to coat tablets with gastro-resistant polymers. Coating gelatin capsules is not a common 
industrial practice (Cerea et al., 2008) and a more common approach is to fill enteric coated granules 
or pellets into a conventional hard gelatin capsule. Hence, the allegedly simpler solid dosage form, 
becomes ever more complex. Therefore, if capsule shells can be prepared with built-in 
gastroresistance, they can be produced in bulk in a similar way to standard capsules. using a typical 
high-speed capsule filler This will have wide applications in controlling drug release and gastrointestinal 
targeting as it would also allow encapsulation of almost any drug or nutraceutical into empty shells for 
preclinical and clinical evaluation without extensive formulation development and can potentially reduce 
the research and development cost. 
Previous attempts to produce enteric hard capsules have been reported in literature, however these 
rely on an additional coating step (AstraZeneca, 2017; Huyghebaert et al., 2004; Miller et al., 2015; 
Sharma and Sinha, 2018) or the incorporation of a gum which would provide protection to acid-sensitive 
ingredients by a delayed-release mechanism, such as DRCaps™ (Smith et al., 2010; Marzorati et al., 
2015). These formulations do not exhibit a pH triggered release and instead rely on a time-delay in 
anticipation of timely emptying from stomach. Gastric emptying in reality is highly unpredictable 
(McConnell et al., 2008, Varum et al., 2010) rendering these products more vulnerable to inter- and 
intra-subject variability in gastric emptying (Davis et al., 1984; Ziessman et al., 2009), hence significantly 
affecting its gastroresistant functionality. Recently, Capsugel® and BioCaps® has developed cellulose 
based drug delivery technologies (enTRinsic™ and Bio-VXR respectively) which are claimed to provide 
full enteric protection without the need for functional coatings (Capsugel®, 2019b) (BioCaps®, 2019), 
however full composition is not disclosed and evidence of clinical efficacy is also very limited. Capsules 
based on acrylic polymers such as EUDRAGIT are not yet reported in the literature. Thus, in this work, 
we aimed to develop gastroresistant capsule shells using three of the most commonly used polymers 
in pharmaceutical industry for formulating gastroresistant dosage forms: hydroxypropyl methyl cellulose 
acetate-succinate (HPMC AS) and hydroxypropyl methyl cellulose phthalate (HPMC-P) and Methacrylic 
Acid - Methyl Methacrylate (Eudragit®).  
  
2. Materials and Methods 
2.1. Materials 
The acrylic (Eudragit® L100 and S100) and cellulose based (HPMC AS-LF and HP-55) enteric polymers 
were provided in-kind as samples from Evonik Industries AG (Darmstadt, Germany) and Shin-Etsu 
(Chiyoda, Japan), respectively and their properties are summarised in Table 1. Sodium hydroxide, 
hydrochloric acid (37%) and ethanol were purchased from Fisher Scientific (Loughborough, United 
Kingdom). Glycerol, lactose monohydrate, triethyl citrate and trisodium phosphate dodecahydrate ≥98% 
were purchased from Sigma-Aldrich (Dorset, United Kingdom). Ac-Di-Sol® SD-711 (croscarmellose 
sodium) and Kollidon® 30 (povidone) were provided in kind by FMC Health and Nutrition (Ireland). 
Prednisolone was purchased from Severn Biotech, Ltd. 
Table 1: Enteric polymers used in this study and their characteristics. 
Polymer Brand name Grade 
Dissolution 
pH threshold 
Manufacturer/ supplier 
Methacrylic acid 
copolymer 
EUDRAGIT® 
L100 6.0 
Evonik Gmbh, 
Darmstadt, Germany 
S100 7.0 
Hypromellose 
acetate succinate 
Aqoat® AS-LF 5.5 
Shin-Etsu Chemical Co., 
Ltd., Japan Hypromellose 
phthalate 
- HP-55 5.5 
2.2. Design and manufacture of capsule pin bars 
For the production of capsules, two sets of pins (capsule moulds) were fabricated with different 
dimensions: one for the body of the capsule and a second for the cap. Capsule pin bars were designed 
and manufactured in-house for a standardized capsule size “00”, according to the reported dimensions 
for this size (Jones, 2004). The pins were produced using pharmaceutical grade stainless steel (316SS) 
rods, which were then machined to produce the pins of desired dimensions (Fig. 1A).  
2.3. Production of hard capsules  
To produce the capsule shells, the pins from Fig. 1A were immersed into the capsule formulation 
containing a gastroresistant polymer and other excipients. The pins were then withdrawn, inverted and 
the solution was allowed to dry to harden the shells, forming the cap and body of the capsule. The caps 
and bodies were then removed from the pins and cut to the desired length. At this stage, the capsule 
components were filled and assembled, forming a finished loaded capsule (Fig 1B). 
2.3.1. Capsule formulation  
Capsules were formulated using different concentrations of polymer (20-30%) plasticised either with 
triethyl citrate (TEC) or glycerol at different concentrations (0-40%). The tested formulations are 
summarised in Table 2. The polymer concentration was key in obtaining a capsule with appropriate 
thickness that could be easily removed from the pins. The polymer concentration also governs the 
viscosity of the prepared solution. An optimum viscosity is essential for the polymer to adhere to the 
pins during the drying process and produce a uniform capsule with the appropriate shape. The type and 
concentration of plasticiser impacts upon the capsule shell elasticity and prevents brittleness.           
 Fig. 1: Schematic representation of [A] capsule forming pins and [B] the capsule. The pins were immersed in 
polymeric solution, inverted and allowed to dry, forming the cap and body of the capsule. 
Table 2: Composition of various formulations to produce gastroresistant capsule shells.  
Formulation ID Polymer % Plasticiser % Solvent 
1.1 
HP-55 
20.0 Glycerol  20.0 
Ethanol : Water  
(80:20a) 
1.2 20.0 TEC  20.0 
1.3 22.5 Glycerol  20.0 
1.4 22.5 Glycerol  30.0 
2.1 
AS-LF 
20.0 Glycerol  20.0 
Ethanol : Water  
(80:20a) 
2.2 20.0 TEC  20.0 
2.3 22.5 Glycerol  20.0 
2.4 25.0 Glycerol  20.0 
2.5 25.0 Glycerol  30.0 
3.1 
EUD 
L100 
20.0 Glycerol 20.0 
Ethanol : Water 
(97:3a) 
3.2 20.0 TEC 20.0 
3.2 25.0 TEC 20.0 
3.4 25.0 TEC 30.0 
3.5 27.5 TEC  20.0 
3.6 27.5 TEC  30.0 
3.7 27.5 TEC 40.0 
4.1 
EUD 
S100 
25.0 TEC 40.0 
Ethanol : Water 
(97:3a) 
4.2 27.5 TEC 40.0 
HP-55 = Hypromellose phthalate-55; AS-LF = Hypromellose acetate succinate – LF;  
EUD L100 = Eudragit L100; EUD S100 = Eudragit S100; TEC = Triethyl citrate. 
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2.4. Tensile studies of produced capsules 
The mechanical properties of the polymeric materials used in the production of the capsules were 
studied using a TA.XT2 Texture analyser (Stable Micro Systems Ltd, Surrey, UK) equipped with tensile 
grips (tensile mode) and a cylinder probe (P/0.5’’R; compressive mode). The films of each polymer were 
produced with the same formulation used for the capsules, casted on a flat surface and allowed to dry 
in the same conditions as the capsules would be. The thickness of the films was controlled by calculating 
the area of the surface where the film was casted, and constantly using a similar ratio of mass of 
polymer/area as it would be when using each formulation to produce the capsules. The films were then 
cut in dog-bone shaped pieces according to DIN EN ISO 527-2 for the determination of tensile 
properties, consisting of a rectangular area of 40x8mm. For each sample an average thickness was 
acquired, and the stress area was calculated. The tests were performed at a speed of 0.5mm/sec, at 
20 C, with 10 replicates per sample. The slope of the linear range of the obtained stress vs. strain 
curves (tensile mode) is equal to the Young’s modulus for the respective polymeric films. 
2.5. Prednisolone filled gastroresistant capsules  
All prepared capsules were filled with prednisolone granules prepared by wet granulation. Briefly, the 
formulation contained prednisolone (5%), lactose monohydrate (88%), Kollidon® 30 (5%), Ac-Di-Sol® 
SD-711 (2%). The ingredients were mixed using a Caleva Multi Lab (Caleva Process Solutions Ltd, 
England). The wet mass was then extruded and the extrudate was spheronized using the corresponding 
module from the Caleva Multi Lab followed by drying at 60 C. The granules were then filled manually 
into capsule shells to an equivalent of 10mg prednisolone per capsule.  
2.6. Drug release from prednisolone-filled gastroresistant capsules 
The drug release from prednisolone-filled capsules was tested using USP-II dissolution apparatus (PT-
DT70 Dissolution Apparatus, Pharma Test Apparatebau AG, Germany). Six capsules were tested for 
each successfully prepared formulation following the USP <711> Dissolution monograph for delayed-
release dosage forms. Briefly, AS-LF, HP-55 and EUD L100 capsules were firstly tested in 0.1M HCl 
(pH 1.2) for 120 min at 37°C, followed by pH 6.8 phosphate buffer (0.05M Na3PO4, pH adjusted with 
1M HCl / 1M NaOH) or pH 6.8 mHanks buffer (Liu et al., 2011) (136.9 mM NaCl, 5.37 mM KCl, 0.812 
mM MgSO4·7H2O, 1.26 mM CaCl2, 0.337 mM Na2HPO4·2H2O, 0.441 mM KH2PO4, 4.17 mM NaHCO3, 
pH adjusted to 6.8 using CO2 (g)). Capsules of EUD S100 were also produced and tested, however, 
since this polymer was designed to target the distal gut, the dissolution testing included two media 
changes to reflect the aboral changes in pH down the intestine. The capsules were firstly tested in 0.1M 
HCl (pH1.2 for 2 hours) to represent gastric conditions followed by a change to pH 6.8 (for 4 hours) to 
simulate the pH of the proximal small intestine. Finally, the pH was adjusted to 7.4 for the rest of the 
experiment simulating the distal small intestine. Like other capsules, the test was conducted in both 
phosphate and mHanks buffers, as described above in this section. For mHanks buffer, the pH change 
from pH 6.8 to 7.4 was performed in situ by sparging helium and the pH was then maintained during 
the dissolution studies by sparging CO2, as described by Liu et al. (2011). 
The release of prednisolone from HPMC AS-LF and EUDRAGIT capsules was quantified using an in-
line UV spectrophotometer (Unicam UV/Vis UV2-200 spectrophotometer) at a wavelength of 246nm. 
For the capsules containing HP-55, the release of the drug was quantified by HPLC-UV due to 
interference between the UV absorbance of the polymer and drug. The HPLC-UV system used was a 
Shimatzu LC-20AT with SIL-20A autosampler and an SPD-20AV UV detector. The samples were 
filtered through 0.2µm syringe filters (Sartorius™ Minisart™ High Flow) and injected into a reverse 
phase C8 (5µm particle size, 4.6x150mm) column (Waters, Massachusetts, USA). The column was 
heated to 40°C and the mobile phase consisted of a mixture of water:tetrahydrofuran:methanol 
(68.8:25:6.2 v/v) flowing at 1.5mL/min. Prednisolone was detected at 254nm, at retention time of 2.7min 
(Liu et al., 2011). 
  
3. Results and discussion 
3.1. Optimisation of capsule formulation 
Various polymeric formulations were tested to achieve optimum gastro-resistance from each enteric 
polymer. Table 3 summarises the final optimised formulation for each polymer that produced to a 
capsule with appropriate thickness, smoothness and gastroresistance. Lower concentrations of polymer 
and plasticiser yield thinner capsules, which either break during their removal from the pins or during 
handling. Lower concentrations of plasticiser also caused striations to appear along the capsule body 
during the drying process. 
Table 3: Composition of optimised capsule formulations for each enteric polymer.  
  HP-55 
HPMC 
AS-LF 
EUDRAGIT®  
L100 
EUDRAGIT® 
S100 
Polymer weight  22.5%a 25%a 27.5%a 27.5%a 
Glycerol  30%b 30%b - - 
Triethyl citrate  - - 40%b 40%b 
Ethanol  80%c 80%c 97%c 97%c 
Water  20%c 20%c 3% 3% 
a: based on total weight, b: based on polymer weight, c: based on solvent weight 
All capsules were cut to appropriate length for “00” size (Jones, 2004) and their diameter was measured 
with a digital micrometer (Table 4). The produced capsules are shown in Fig 2. The dimensions of 
optimised capsule formulations were in accordance with the size and tolerances used by commercial 
suppliers of hard gelatin capsules (Capsugel®, 2019a). 
Fig. 2: Capsules obtained from optimised formulations for EUD L100 (A), AS-LF (B), HP-55 (C) and EUD S100 (D). 
 
Table 4: Dimensions (mean  STD, n=6) for the size “00” capsules produced from optimised formulations.  
 HP-55 HPMC AS-LF L100 S100 
 Body Cap Body Cap Body Cap Body Cap 
Outer Diameter 
(mm) 
8.51  
0.04 
8.18  
0.04 
8.52  
0.03 
8.17 
0.03 
8.53  
0.04 
8.16  
0.02 
8.52  
0.05 
8.17  
0.02 
Thickness (mm) 0.104  
0.02 
0.097  
0.01 
0.119  
0.01 
0.104  
0.02 
0.108  
0.02 
0.114  
0.02 
0.115  
0.02 
0.109  
0.01 
 
3.2. Tensile strength  
From the stress vs strain plots obtained from the tensile tests on the polymeric films (Fig. 3), the elastic 
moduli were calculated and are summarised in Table 5. The measured Young’s moduli of the polymers 
used in this work are comparable to reported values of gelatin used to formulate capsules (de Carvalho 
and Grosso, 2006; Park et al., 2007), exhibiting resistance to elastic deformation similar to that of 
standard gelatin capsules. It is worth noticing a lower yield point for the EUD S100 profile (Fig. 3), which 
is in line with brittleness of the S100 formulated capsules. Although the yield point was comparatively 
lower for these capsules (~5MPa), it may not adversely affect the mechanical stability of the capsule 
during packaging, storage or transportation. The Young’s modulus for these films also suggests the 
resistance to elastic deformation was comparable to other polymers. Moreover, S100 capsules met the 
acid challenge test and the subsequent drug release in buffer was also satisfactory (refer s. 3.3 for 
further details). 
  
Fig. 3: Stress vs strain plots of HP-55, EUD L100, AS-LF and EUD S100 polymeric films. The slope of the linear 
region in profiles relates to the Young’s modulus.  
Table 5: Young’s modulus of polymeric films used to formulate capsules shells. The values represents average  
STD (n=9).    
Polymer Young’s modulus (MPa) 
HPMC AS-LF  15.61  2.10 
HP-55 17.38  0.83 
EUD L100 13.84  2.98 
EUD S100 16.66  2.90 
Gelatin 19.5  1.6a; 
15.12  0.05 b 
a: (Park et al., 2007); b: (de Carvalho and Grosso, 2006)  
3.3. Drug release from produced capsules 
Prednisolone release from optimised formulations (Table 3) for HPMC AS-LF, HP-55 and Eudragit L100 
capsules is shown in Fig. 4A. There was no drug released during the first 2 hours in acid, confirming 
the acid resistance of the dosage forms as per pharmacopoeial requirements. All capsules ruptured 
rapidly exhibiting a drug release within ~5min on transfer to pH 6.8 50mM compendial phosphate buffer. 
The drug release from enteric capsules was therefore comparable to equivalent polymer-coated 
conventional gastroresistant tablets (Liu et al.,2011).  
As expected, drug release in physiological bicarbonate buffer was delayed significantly and profiles 
between different polymers were not superimposable. Despite HPMC AS-LF and HP-55 being 
marketed for a dissolution pH threshold above pH 5.5, their release profiles in bicarbonate buffer were 
discriminatory, despite being similar in phosphate buffer. Interestingly, prednisolone release from 
HPMC AS-LF capsules was similar in compendial phosphate and bicarbonate buffers, with a lag-time 
(time until at least 1% of drug is released) in the bicarbonate buffer of around 15 min compared to 
around 5 min in phosphate buffer. However, for HP-55 this lag time was much longer in bicarbonate 
buffer with no drug released until an hour in buffer. Eudragit L100 exhibited highest lag-time when tested 
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in bicarbonate buffer, with the drug release delayed for 2 hours after transferring to the buffer phase. 
The much-delayed release of the drug from enteric capsules in physiological bicarbonate buffer was 
not surprising and also complies with previous reports of drug release behaviour from conventional 
enteric polymer-coated tablets in bicarbonate buffer (Liu et al. (2011). 
 
Fig. 4: Prednisolone release from enteric capsules (n=6) in 50 mM compendial phosphate buffer (empty symbols) 
and physiological bicarbonate buffer, mHanks (filled symbols). [A]: HP-55, EUD L100 and AS-LF capsules at pH 
6.8, after 2 h-exposure to 0.1M HCl (not shown); [B]: EUD S100 capsules at pH 7.4 following 2 h in 0.1M HCl and 
4 h in pH 6.8 buffer. 
This suggests that the behaviour of the enteric polymers is similar when used as coatings on 
conventional tablets or to produce capsule shells. Although longer lag-times are observed for enteric 
capsules (Table 6) as compared with coated tablets in Liu et al. (2011), these can be attributed to the 
differences in the thickness of the capsule shells compared to the thickness of an enteric coating film 
applied to a tablet. The thickness of a typical coating on gastroresistant tablet varies about 50 to 75 
microns with tablet edges usually thinly coated than the sides (Merchant, 2012), hence, coating around 
the edges mainly controls the lag-time in drug release. The enteric capsule shells on the other hand 
exhibited a uniform thickness ~100 microns (Table 4) which is twice more than the classic film coating. 
Nevertheless, the order in which the polymers start dissolving and the capsules start releasing the drug 
is the same as previously reported for coated tablets (Liu et al., 2011), exhibiting a rank order of time 
until drug release of HPMC AS-LF< HP-55< EUD L100. ASLF and HP-55 capsules are therefore 
suitable for gastroresistant applications to target the drug in proximal gastrointestinal tract, such as 
Deltacortil®, Nexium®, Voltarol®, Pariet® etc.  
Table 6: Lag time for the drug release (1% release) from polymeric capsules and from conventional polymer-coated 
tablets at pH 6.8 (EUD L100, HP-55 and AS-LF) or pH 7.4 (EUD S100), pre-exposed to 0.1M HCl pH 1.2 for 2h. 
Data from polymer-coated tablets from Liu et al. (2011) and Ibekwe et al. (2006). 
 Lag times (min) in phosphate buffer Lag times (min) in bicarbonate buffer 
 HP-55 AS-LF EUD L100 EUD S100 HP-55 AS-LF EUD L100 EUD S100 
Gastroresistant 
Capsules 
3.2 
1.6 
2.2 
0.4 
15.0 
1.4 
16.0 
4.0 
67.5 
2.9 
18.2 
2.7 
130.4 
18.3 
237.3 
8.1 
Coated Tablets  5[1] 15[1] 11[1] 65[2] 35[1] 32[1] 77[1] 130[2] 
HP-55 = Hypromellose phthalate-55; AS-LF = Hypromellose acetate succinate – LF; EUD L100 = Eudragit L100;  
EUD S100 = Eudragit S100. [1] Liu et al. (2011), [2] Ibekwe et al. (2006) 
The drug release profile from EUD S100 capsules is shown in Fig. 4B. These capsules were subjected 
to two media changes, the first to pH 6.8 and the second to pH 7.4. As expected, no drug release 
occurred during the acid phase (confirming gastroresistance) and in pH 6.8 (both in phosphate and 
bicarbonate buffers) however the drug was released at pH 7.4 within 15 min in phosphate buffer and a 
much-delayed release in bicarbonate buffer (~4 hours). This slower release in bicarbonate buffer is not 
unexpected and longer lag times in this buffer were already reported by Goyanes et al. (2015). 
Therefore, L100/S100 based capsules are promising candidates to target pharmaceutical/nutraceutical 
agents to the distal gastrointestinal tract, such as Asacol®, Octasa®, Salofalk®, pre/probiotics etc. The 
drug release from these capsules, however, can be improved by further optimising the capsule shell. 
For instance; using pH responsive polymer blends, such as: S100/L100. A dual trigger system (pH and 
bacteria) comprising two independent but complementary release mechanisms can be embedded in 
capsule shells. This fail-safe system has recently shown promising results in the clinic in delivering high 
dose oral mesalazine to inflammatory bowel disease patients (D'Haens et al., 2017).  
Intra- and inter-tablet coating variability in coated dosage forms is a significant factor responsible for 
the huge pharmacokinetics variability exhibited by these dosage forms for example Deltacortil 
(Merchant, 2012), which is further confounded by other variables such as gastric emptying time 
(McConnell et al., 2008). The capsules produced in this work do not need an additional coating step, 
and once translated to industrial production, the controllable and low variability of capsule wall thickness 
may reduce in-vivo variability associated with coating inconsistency in conventional products. Moreover, 
gastrointestinal targeting may be easily achieved by bespoke capsules shells produced at large scale 
where drug release can be tailored by the polymer blend and capsule wall thickness.  
 
  
4. Conclusion  
We have successfully produced gastroresistant capsule shells that do not need additional coating to 
provide gastroresistance. A range of enteric polymers (HPMC derivatives and acrylate-based polymers) 
were used to produce enteric capsule shells to target various regions within the GI tract: 
duodenum/jejunum – HPMC AS-LF and HP-55 (pH 5.5); ileocolonic – EUD L100 (pH 6.0); colon – EUD 
S100 (pH 7.0). The produced capsules were very similar to classic immediate release hard gelatin 
capsules in appearance and resistance to elastic deformation. The technology, if warranted at industrial 
scale, can allow production of capsule shells in bulk, similar to conventional capsules, and will enable 
the industry to produce gastroresistant dosage forms without coating on a conventional capsule filling 
line. This will also be beneficial in early discovery and development in formulating gastroresistant 
dosage forms for preclinical and clinical trials.  
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